Stagezero begins COVID-19 testing for travel to China $$$$$$ 2020-12-02 15:52 ET - News Release
Mr. James Howard-Tripp reports
STAGEZERO LIFE SCIENCES ANNOUNCES INITIATION OF TESTING FOR TRAVEL TO CHINA
Stagezero Life Sciences Ltd. has initiated COVID-19 testing for travel to China with its partners in Canada.
China requires both PCR and IgM testing 72 hours prior to travel into the country. The testing is currently offered in Calgary and will be expanding into Ontario and British Columbia. This is the most recent significant travel-related initiative that the company has partnered on. The first was a large global travel group, and subsequent partnerships include the government of Barbados (announced Nov. 13, 2020) and the state of Hawaii.
"Not only does testing prior to travel help reduce the strain on a nation's health care system, it allows travellers to enjoy an element of normal life once they arrive, if their destination is COVID-19 free," said James Howard-Tripp, chairman and chief executive officer of Stagezero Life Sciences.
Further developments
In addition to new partnerships, the company has extended and expanded testing services to the county in Arizona that it has been servicing since early in 2020. Due to the surge in COVID-19 cases, the county is increasing both testing sites and access to testing. Further, testing has been extended to the judicial department and jurors. Stagezero will be providing these services into 2021.
The company will schedule an analyst-update call next week on the recently released Q3 financials and will also provide an update on Aristotle. Further details will be released.
The company's financial statements and management discussion and analysis are available on SEDAR.
About Stagezero Life Sciences Ltd.
Stagezero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The company operates a CAP-accredited and CLIA-certified high-complexity reference laboratory based in Richmond, Va. A specialist in PCR testing for the early identification of cancer through blood, the company is uniquely positioned to provide both COVID-19 PCR testing (swab) and blood test analysis (antibody testing). Its full-service telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As the company provides COVID-19 tests during this pandemic, it continues making progress with its mission to eradicate late-stage cancers through early detection. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.